CytomX Therapeutics, Inc. (CTMX) Free cash flow 2016–2025
CytomX Therapeutics, Inc. (CTMX) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$75.8MFY2025 · since FY2016: -$4.2M → -$75.8M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$75.8M | +12.4% |
| FY2024 | -$86.5M | -52.2% |
| FY2023 | -$56.9M | +49.5% |
| FY2022 | -$112.5M | +6.7% |
| FY2021 | -$120.6M | -4189.5% |
| FY2020 | $3.0M | +102.0% |
| FY2019 | -$144.0M | -81.5% |
| FY2018 | -$79.3M | -147.0% |
| FY2017 | $168.8M | +4111.7% |
| FY2016 | -$4.2M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More CTMX financial trends
CTMX RevenueCTMX Net incomeCTMX Net marginCTMX Gross profitCTMX Gross marginCTMX Operating incomeCTMX Operating marginCTMX Operating cash flowCTMX Capital expendituresCTMX Return on equityCTMX Stock buybacksCTMX Dividends paidCTMX Total assetsCTMX Total liabilitiesCTMX Shareholders’ equityCTMX overview →